Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Abstract The Human Epidermal Growth Factor Receptor (HER) proteins family, which
includes HER2, are membrane-bound receptors that activate many intracellular pathways …

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic
targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …

The increasing number of approved drugs along with next generation sequencing (NGS)
technologies look out as potential revolution of biomolecular characterization of non-small …

The mortality of lung cancer is surprising, even though the development of different
treatments and diagnosis methods. Besides, non-small cell lung cancer (NSCLC) takes a …